NGM reported results from its 24-week phase 2 trial that was testing its experimental drug called aldafermin as a hopeful treatment for non-alcoholic steatohepatitis (NASH). Here are the key takeaways …
More Here’s Why NGM Biopharmaceuticals Is Soaring Today Videos